-
Strengthening the foundation of African microbiome research: strategies for standardized data collection Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-09-19 Soumaya Kouidhi, Ovokeraye H. Oduaran
The current state of microbiome research in Africa can be leveraged to encourage the development and implementation of standardized processes for data collection and management. In this Comment, we provide some recommendations to enable the research community to fully harness the richness of the microbiome of African populations and potential opportunities therein.
-
TREM2 macrophages mediate the beneficial effects of bariatric surgery against MASH Hepatology (IF 12.9) Pub Date : 2024-09-18 Gavin Fredrickson, Kira Florczak, Fanta Barrow, Shamsed Mahmud, Katrina Dietsche, Haiguang Wang, Preethy Parthiban, Andrew Hakeem, Rawan Almutlaq, Oyedele Adeyi, Adam Herman, Alessandro Bartolomucci, Christopher Staley, Xiao Dong, Cyrus Jahansouz, Jesse W. Williams, Douglas G. Mashek, Sayeed Ikramuddin, Xavier S. Revelo
For patients with obesity and metabolic syndrome, bariatric procedures such as vertical sleeve gastrectomy (VSG) have a clear benefit in ameliorating metabolic dysfunction-associated steatohepatitis (MASH). While the effects of bariatric surgeries have been mainly attributed to nutrient restriction and malabsorption, whether immuno-modulatory mechanisms are involved remains unclear. Using murine models
-
Prevalence of subclinical hypothyroidism and longitudinal thyroid stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease: an observational study Hepatology (IF 12.9) Pub Date : 2024-09-18 Matthew Untalan, Nancy Crimmins, Katherine P. Yates, Ali Mencin, Stavra Xanthakos, Vidhu V. Thaker
Background: Studies on adults have shown an association between overt or subclinical hypothyroidism (SH) and metabolic dysfunction-associated steatotic liver disease (MASLD). The goal of this study was to assess the relationship between thyroid-stimulating hormone (TSH) levels and the histological characteristics of MASLD in youth. Methods: This observational study used prospectively collected liver
-
Letter to the Editor: Benchmarking clinical risk prediction algorithms with ensemble machine learning for the non-invasive diagnosis of liver fibrosis in NAFLD Hepatology (IF 12.9) Pub Date : 2024-09-18 Yanfei Yang, Xu Luo, Shimeng Cui, Zhikun Lin
-
Uncovering epigenetic heterogeneity in hepatocellular carcinoma Hepatology (IF 12.9) Pub Date : 2024-09-18 Yousra Ajouaou, Kirsten C. Sadler
-
Disparity landscapes of viral-induced structural variations in hepatocellular carcinoma: Mechanistic characterization and functional implications Hepatology (IF 12.9) Pub Date : 2024-09-13 Xueying Lyu, Karen Man-Fong Sze, Joyce Man-Fong Lee, Abdullah Husain, Lu Tian, Sandrine Imbeaud, Jessica Zucman-Rossi, Irene Oi-Lin Ng, Daniel Wai-Hung Ho
Oncoviruses can integrate into the host genome and cause tumorigenesis. In particular, hepatitis B virus (HBV) infection accounts for more than 50% of hepatocellular carcinoma (HCC) worldwide. We revealed the global geographical disparity of HBV integration that the landscape of HBV integration between HCC tumor and non-tumorous liver varied in regional cohorts, suggesting the different degrees of
-
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-09-12 Giovanni Cammarota, Gianluca Ianiro
Gastroenterology as a specialty can make a substantial contribution to reducing the carbon footprint of the health-care system. Concrete actions are needed to increase awareness, education and evidence-based knowledge on eco-sustainable diagnostic and therapeutic approaches to digestive diseases.
-
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy Hepatology (IF 12.9) Pub Date : 2024-09-12 Patricia P. Bloom, Caitlyn J. Fisher, Nicholas Tedesco, Neil Kamdar, Luis Garrido-Trevino, Jessica Robin, Sumeet K. Asrani, Anna S. Lok
Background & Aims: Hepatic encephalopathy (HE) is a major cause of poor quality of life in patients with cirrhosis. A simple diagnostic test to identify minimal HE (MHE) and predict future overt HE (OHE) is lacking. We aimed to evaluate if analysis of speech patterns using a modern speech platform: 1) correlates with validated HE tests, 2) correlates with MHE, and 3) predicts future OHE. Approach &
-
Global differences in the management of alcohol-associated hepatitis. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-10 Hanna Blaney,Luis Antonio Díaz,Nhi Li,Gurpreet Malhi,Rokhsana Mortuza,Xiaolong Qi,Anand V Kulkarni,Ramon Bataller,Joaquin Cabezas,Alexandre Louvet,Elliot B Tapper,Juan Pablo Arab
-
Predictors of long-term clinical outcomes after TIPS: An ALTA group study. Hepatology (IF 12.9) Pub Date : 2024-09-10 Yael R Nobel,Justin R Boike,Nikhilesh R Mazumder,Bartley Thornburg,Rachel Hoffman,K Pallav Kolli,Michael Fallon,Jennifer C Lai,Giuseppi Morelli,Erin K Spengler,Adnan Said,Archita P Desai,Sonali Paul,Aparna Goel,Kelly Hu,Catherine Frenette,Dyanna Gregory,Cynthia Padilla,Yuan Zhang,Lisa B VanWagner,Elizabeth C Verna,
BACKGROUND AND AIMS While transjugular intrahepatic portosystemic shunt (TIPS) is traditionally considered a bridge to liver transplant (LT), some patients achieve long-term transplant-free survival (TFS) with TIPS alone. Prognosis and need for LT should not only be assessed at time of procedure, but also re-evaluated in patients with favorable early outcomes. APPROACH AND RESULTS Adult TIPS recipients
-
Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort. Hepatology (IF 12.9) Pub Date : 2024-09-10 Binu V John,Dustin Bastaich,Mahmoud Manouchehri Amoli,Robert J Wong,Donna M Evon,Shari S Rogal,David B Ross,Timothy R Morgan,Seth A Spector,Gabriel Villada,Hann-Hsiang Chao,Bassam Dahman,
BACKGROUND Hepatitis Delta Virus (HDV) infection is the most severe form of chronic hepatitis. However, studies on outcomes and causes of death in a United States-born population, with primarily horizontal transmission of HDV, are lacking. The aim of this study was to conduct a national study of patients with hepatitis D to understand the natural history and outcomes compared to patients with hepatitis
-
HAF prevents hepatocyte apoptosis and progression to MASH and hepatocellular carcinoma through transcriptional regulation of the NF-κB pathway Hepatology (IF 12.9) Pub Date : 2024-09-10 Karen Acuña-Pilarte, Ethan C. Reichert, Yangsook Song Green, Lily M-T. Halberg, Martin Golkowski, Kathleen M. Maguire, Patrice N. Mimche, Severin Donald Kamdem, Po-An Hu, Jillian Wright, Gregory S. Ducker, Warren P. Voth, Ryan M. O’Connell, Sydney A. McFarland, Erika Said Abu Egal, Amandine Chaix, Scott. A. Summers, Jordan W. Reelitz, J. Alan Maschek, James E. Cox, Kimberley J. Evason, Mei Yee Koh
Background: HCC incidence is increasing worldwide due to the obesity epidemic, which drives metabolic dysfunction-associated steatohepatitis (MASH) that can lead to HCC. However, the molecular pathways driving MASH-HCC are poorly understood. We have previously reported that male mice with haploinsufficiency of hypoxia-associated factor, HAF (SART1 +/-) spontaneously develop MASH-HCC. However, the cell
-
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Yuan Sun,Yan Li,Kezhen Zong,Ning Jiang,Baoyong Zhou
-
Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Hannes Hagström,Ying Shang,Hannes Hegmar,Patrik Nasr
The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long. A minority of patients develop inflammation and risk progressive fibrosis that can result in cirrhosis. Progression to cirrhosis occurs in 3-5% of patients and often takes more than 20 years. This narrative review presents
-
Irritable bowel syndrome: an urgent issue. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Chrissie Pearson
-
Blood tests for colorectal cancer: practical or premature? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 The Lancet Gastroenterology Hepatology
-
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? - Author's reply. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Eduard A van Bodegraven,Alberto Balduzzi,Tess M E van Ramshorst,Giuseppe Malleo,Frederique L Vissers,Jony van Hilst,Giovanni Marchegiani,Matteo de Pastena,Roberto Salvia,Casper H J van Eijck,Marc G Besselink,
-
Augmenting colonoscopy with AI: insights and future directions. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Sravanthi Parasa
-
Characterizing the genomic landscape of colorectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-09-09 Jordan Hindson
A study published in Nature elucidates the genomic landscape of colorectal cancer (CRC). Researchers performed whole-genome sequencing of CRC samples from participants in the UK 100,000 Genomes Project. Analysis of the samples (n = 2,023) identified >250 putative driver genes of CRC and characterized subgroups of CRC. For example, the researchers clustered microsatellite-stable CRC into four distinct
-
Ammonia-induced stress response in liver disease progression and hepatic encephalopathy Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-09-09 Rocío Gallego-Durán, Anna Hadjihambi, Javier Ampuero, Christopher F. Rose, Rajiv Jalan, Manuel Romero-Gómez
-
Stretch-induced hepatic endothelial mechanocrine promotes hepatocyte proliferation Hepatology (IF 12.9) Pub Date : 2024-09-09 Yi Wu, Linda Li, Wang Li, Ning Li, Xiaoyu Zhang, Lu Zheng, Shaoyu Zhong, Shouqin Lü, Xinyu Shu, Jin Zhou, Ding Ai, Ming Gao, Sijin Liu, Dongyuan Lü, Mian Long
Background & Aims: Partial hepatectomy (PHx)-induced liver regeneration causes the increase in relative blood flow rate within the liver, which dilates hepatic sinusoids and applies mechanical stretch on liver sinusoidal endothelial cells (LSECs). Heparin-binding EGF-like growth factor (HB-EGF) is a crucial growth factor during liver regeneration. We aimed to investigate whether this sinusoidal dilation-induced
-
HKDC1 promotes liver cancer stemness under hypoxia via stabilizing β-catenin Hepatology (IF 12.9) Pub Date : 2024-09-09 Li Fan, Cheng Tian, Wentao Yang, Xiaoli Liu, Yogesh Dhungana, Wenjian Yang, Haiyan Tan, Evan S. Glazer, Jiyang Yu, Junmin Peng, Lichun Ma, Min Ni, Liqin Zhu
Background and Aims: Hexokinases (HKs), a group of enzymes catalyzing the first step of glycolysis, have been shown to play important roles in liver metabolism and tumorigenesis. Our recent studies identified HKDC1 as a top candidate associated with liver cancer metastasis. We aimed to compare its cell type specificity with other HKs upregulated in liver cancer and investigate the molecular mechanisms
-
Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis Hepatology (IF 12.9) Pub Date : 2024-09-09 Zobair M. Younossi, Maria Stepanova, Andrei Racila, Linda Henry, Dominic Labriola, Rebecca Taub, Fatema Nader
Background/Aims: Resmetirom, liver directed thyroid-hormone receptor-β agonist, received approval for MASH treatment. We assessed HRQL in MASH patients treated with resmetirom. Methods: Non-cirrhotic MASH/NASH patients with confirmed/suspected fibrosis were enrolled in a 54-month double-blind randomized placebo-controlled Phase 3 clinical trial with serial biopsy assessments (MAESTRO-NASH, NCT03900429)
-
Central role for cholangiocyte pathobiology in cholestatic liver diseases Hepatology (IF 12.9) Pub Date : 2024-09-09 Nidhi Jalan-Sakrikar, Maria Eugenia Guicciardi, Steven P. O’Hara, Adiba Azad, Nicholas F. LaRusso, Gregory J. Gores, Robert C. Huebert
Cholangiopathies comprise a spectrum of chronic intra- and extrahepatic biliary tract disorders culminating in progressive cholestatic liver injury, fibrosis and often cirrhosis and its sequela. Treatment for these diseases is limited and collectively they are one of the therapeutic “black boxes” in clinical hepatology. The etiopathogenesis of the cholangiopathies likely includes disease-specific mediators
-
Efficacy and safety of infliximab in patients with autoimmune hepatitis Hepatology (IF 12.9) Pub Date : 2024-09-09 Cumali Efe, Ellina Lytvyak, Tuğçe Eşkazan, Rodrigo Liberal, Theodoros Androutsakos, Dilara Turan Gökçe, Benedetta Terziroli Beretta-Piccoli, Maciej Janik, Christine Bernsmeier, Pinelopi Arvaniti, Piotr Milkiewicz, Ersin Batıbay, Osman Yüksekyayla, Ilkay Ergenç, Çiğdem Arıkan, Albert Friedrich Stättermayer, Sezgin Barutçu, Mustafa Cengiz, Özlem Gül, Alexandra Heurgue, Michael A. Heneghan, Sumita Verma
Background and Aims: A limited number of drugs are used as standard or alternative therapies in autoimmune hepatitis (AIH). No specific-recommendations are available for patients failing to respond to these therapies. We analyzed the efficacy and safety of infliximab in patients with AIH. Approach and Results: We performed a retrospective study of 42 patients with AIH who received infliximab at 21
-
Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study J. Hepatol. (IF 26.8) Pub Date : 2024-09-08 Parissa Tabrizian M.D. MSc FACS, Matthew L. Holzner M.D., Veeral Ajmera M.D., Amy K. Kim M.D., Kali Zhou M.D., Gabriel T. Schnickel M.D., Kelly Torosian M.D., Maarouf Hoteit M.D., Rebecca Marino M.D., Michael Li M.D., Francis Yao M.D., Sander S. Florman M.D., Myron E. Schwartz M.D., Neil Mehta M.D.
The use of immune checkpoint inhibitors (ICI) in patients with advanced hepatocellular carcinoma (HCC) has become widespread with encouraging outcomes in the neoadjuvant setting. Safety and intention to treat (ITT) outcomes in the peri transplant setting are currently based on small and heterogenous single center reports. This first multiregional US study (2016-2023) included 117 consecutive HCC patients
-
GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-09-06 Jonathan Goldney, Melanie J. Davies
-
AI-based tool for scoring MASH histology Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-09-06 Jordan Hindson
In a study published in Nature Medicine, researchers report an artificial intelligence (AI)-based digital pathology tool for scoring metabolic dysfunction-associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis (NASH)) histology. MASH clinical trial enrollment and endpoint assessment are based on histological criteria. The tool, which is termed AIM-MASH, produced predictions
-
Hepatic immune regulation and sex disparities Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-09-05 Patrizia Burra, Alberto Zanetto, Bernd Schnabl, Thomas Reiberger, Aldo J. Montano-Loza, Rosanna Asselta, Tom Hemming Karlsen, Frank Tacke
-
Cell to cell signaling cross talk in liver regeneration: A prostaglandin-wnt axis Hepatology (IF 12.9) Pub Date : 2024-09-05 Udayan Apte
-
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD Hepatology (IF 12.9) Pub Date : 2024-09-05 Sander Lefere, Antonella Mosca, Christian Hudert, Ellen Dupont, Emer Fitzpatrick, Eirini Kyrana, Anil Dhawan, Laura Kalveram, Andrea Pietrobattista, Anja Geerts, Ruth De Bruyne
-
Letter to the Editor: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD Hepatology (IF 12.9) Pub Date : 2024-09-05 Haowen Zhang, Xinyuan Zhu, Yunfeng Zhou, Yang Yuan
-
Regional disparities of infections in cirrhosis: a call for action. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-04 Nipun Verma,Salvatore Piano
-
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-04 Zhujun Cao,Florence Wong,Ashok K Choudhury,Patrick S Kamath,Mark Topazian,Aldo Torre,Peter C Hayes,Jacob George,Ramazan Idilman,Wai-Kay Seto,Hailemichael Desalegn,Mario Reis Alvares-da-Silva,Brian J Bush,Leroy R Thacker,Qing Xie,Jasmohan S Bajaj,
BACKGROUND Infections have a poor prognosis in inpatients with cirrhosis. We aimed to determine regional variations in infections and their association with clinical outcomes in a global cohort of inpatients with cirrhosis. METHODS In this prospective cohort study initiated by the CLEARED Consortium, we enrolled adults (aged >18 years) with cirrhosis who were non-electively admitted to 98 hospitals
-
Immunobiology of primary sclerosing cholangitis Hepatology (IF 12.9) Pub Date : 2024-09-04 Martin Cornillet, Daniel Geanon, Annika Bergquist, Niklas K. Björkström
Primary sclerosing cholangitis (PSC) is a chronic inflammatory progressive cholestatic liver disease. Genetic risk factors, presence of autoantibodies, the strong clinical link with inflammatory bowel disease (IBD), and associations with other autoimmune disorders all suggest a pivotal role for the immune system in PSC pathogenesis. In this review, we provide a comprehensive overview of recent immunobiology
-
Best buy interventions to address the burden of steatotic liver disease. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-03 Jeffrey V Lazarus,Henry E Mark,Naim Alkhouri,Luis Antonio Díaz,Ajay Duseja,C Wendy Spearman,Maja Thiele,Vincent Wai-Sun Wong,Zobair M Younossi
-
Consequences of bathroom restriction on transgender individuals with gastrointestinal conditions in the United States Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-09-02 Cass D. Condray, Kira L. Newman, Victor G. Chedid
-
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-02 Matthew C Choy,Christopher F D Li Wai Suen,Danny Con,Kristy Boyd,Raquel Pena,Kathryn Burrell,Ourania Rosella,David Proud,Richard Brouwer,Alexandra Gorelik,Danny Liew,William R Connell,Emily K Wright,Kirstin M Taylor,Aviv Pudipeddi,Michelle Sawers,Britt Christensen,Watson Ng,Jakob Begun,Graham Radford-Smith,Mayur Garg,Neal Martin,Daniel R van Langenberg,Nik S Ding,Lauren Beswick,Rupert W Leong,Miles
BACKGROUND The optimal dosing strategy for infliximab in steroid-refractory acute severe ulcerative colitis (ASUC) is unknown. We compared intensified and standard dose infliximab rescue strategies and explored maintenance therapies following infliximab induction in ASUC. METHODS In this open-label, multicentre, randomised controlled trial, patients aged 18 years or older from 13 Australian tertiary
-
Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-02 Saurabh Kedia,Vineet Ahuja
-
Reply to: “No need for complex blood purification systems for renal replacement therapy during long-term liver normothermic machine perfusion” and “The importance of developing viability criteria to assess liver grafts undergoing multi-week normothermic perfusion” J. Hepatol. (IF 26.8) Pub Date : 2024-08-31 Umberto Cillo, Federico Nalesso, Alessandra Bertacco
-
Reply to: “What references and what gold standard should be used to assess myosteatosis in chronic liver disease?” J. Hepatol. (IF 26.8) Pub Date : 2024-08-31 Simone Di Cola, Manuela Merli
-
Reply to: “MetALD accounts for a large part of what we call MASLD!” J. Hepatol. (IF 26.8) Pub Date : 2024-08-31 Wilhelmus J. Kwanten, Benedikt Silvester Hofer, Sven Francque
-
Spontaneous candidemia: A real infection in advanced cirrhosis J. Hepatol. (IF 26.8) Pub Date : 2024-08-31 Sonia Torres, Cautar El Maimouni, Gilberto Herrera, Javier Fernandez
-
Large-scale hepatitis E virus genotype 3 outbreak on new caledonia island Hepatology (IF 12.9) Pub Date : 2024-08-30 Florence Abravanel, Clémence Vignon, Ambroise Mercier, Jean-Baptiste Gaumery, Antoine Biron, Clément Filisetti, Marie-Amélie Goujart, Julien Colot, Xavier Chamillard, Justine Demortier, Maxime Raz, Catherine Boutet, Laura Dupont, Sylvie Duval, Catherine Castric, Denise Desoutter, Anais Desoutter, Marjorie Verge, Clémentine De Smet, Sofia Demmou, Sébastien Lhomme, Ann-Claire Gourinat, Florence Nicot
Background and Aim: Several symptomatic cases of hepatitis E virus (HEV) infections were reported to the New Caledonia Island Public Health Service between August and December 2023. This prompted epidemiological and virological investigations to identify the source of infection. Approach and Results: HEV RNA was assessed in symptomatic patients, various food items and pig farms on the island. HEV strains
-
Intestinal organ chips for disease modelling and personalized medicine Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-08-27 Alican Özkan, Nina Teresa LoGrande, Jessica F. Feitor, Girija Goyal, Donald E. Ingber
-
Functional humoral immunity is crucial to outcomes in severe alcohol-associated hepatitis Hepatology (IF 12.9) Pub Date : 2024-08-27 Brett M. McGettigan, Natalia Osna
-
A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes Hepatology (IF 12.9) Pub Date : 2024-08-27 Peter Saliba-Gustafsson, Johanne M. Justesen, Amanda Ranta, Disha Sharma, Ewa Bielczyk-Maczynska, Jiehan Li, Laeya A. Najmi, Maider Apodaka, Patricia Aspichueta, Hanna M. Björck, Per Eriksson, Theresia M. Schurr, Anders Franco-Cereceda, Mike Gloudemans, Endrina Mujica, Marcel den Hoed, Themistocles L. Assimes, Thomas Quertermous, Ivan Carcamo-Orive, Chong Y. Park, Joshua W. Knowles
Background & Aims: Metabolic dysfunction-associated fatty liver disease (MASLD) is the most prevalent chronic liver pathology in western countries, with serious public health consequences. Efforts to identify causal genes for MASLD have been hampered by the relative paucity of human data from gold-standard magnetic resonance quantification of hepatic fat. To overcome insufficient sample size, genome-wide
-
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD? Hepatology (IF 12.9) Pub Date : 2024-08-27 Yusuf Yilmaz
-
Human induced pluripotent stem cell based hepatic-modeling of lipid metabolism associated TM6SF2 E167K variant Hepatology (IF 12.9) Pub Date : 2024-08-27 Lanuza AP Faccioli, Yiyue Sun, Olamide Animasahun, Takashi Motomura, Zhenghao Liu, Takeshi Kurihara, Zhiping Hu, Bo Yang, Zeliha Cetin, Annalisa M. Baratta, Ajay Shankaran, Minal Nenwani, Leyla Nurcihan Altay, Linqi Huang, Noah Meurs, Jonathan Franks, Donna Stolz, Dillon C. Gavlock, Mark T. Miedel, Alina Ostrowska, Rodrigo M. Florentino, Ira J. Fox, Deepak Nagrath, Alejandro Soto-Gutierrez
Background and Aims: TM6SF2 rs58542926 (E167K) is related to increased prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD). Conflicting mouse study results highlight the need for a human model to understand this mutation’s impact. This study aims to create and characterize a reliable human in vitro model to mimic the effects of the TM6SF2-E167K mutation for future studies
-
Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD? Hepatology (IF 12.9) Pub Date : 2024-08-27 Sander Lefere, Antonella Mosca, Christian Hudert, Ellen Dupont, Emer Fitzpatrick, Eirini Kyrana, Anil Dhawan, Laura Kalveram, Andrea Pietrobattista, Anja Geerts, Ruth De Bruyne
-
Leveraging Generational Differences in the Gastroenterology Workforce to Promote Satisfaction and a Harmonious Work Environment Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Jennifer M. Kolb, Elizabeth Magnan, John M. Carethers, Swati G. Patel
-
Optimising local treatment decisions for rectal cancer. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Krishan R Jethwa,Khush S Aujla,Aurelie Garant
-
Normothermic regional perfusion presents ethical concerns in the USA. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Bryant Furlow
-
Expression of concern-Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 The Editors Of The Lancet Gastroenterology Hepatology
-
Diet or optimised medical therapy for people with irritable bowel syndrome. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Alexander C Ford,Christopher J Black,Michael Camilleri
-
Watch and wait for rectal cancer: towards data-informed surveillance. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Fahima Dossa,Martin R Weiser
-
Diet or optimised medical therapy for people with irritable bowel syndrome. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Christian Lambiase,Giuseppe Chiarioni,Massimo Bellini
-
Diet or optimised medical therapy for people with irritable bowel syndrome - Authors' reply. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Sanna Nybacka,Hans Törnblom,Axel Josefsson,Johann P Hreinsson,Lena Böhn,Åsa Frändemark,Cecilia Weznaver,Stine Störsrud,Magnus Simrén
-
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer - Authors' reply. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Durgesh Wankhede,Michael Hoffmeister
-
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Changjing Cai,Peng Zhang,Ying Han,Hong Shen,Shan Zeng